Evaluation of New Markers in Type 3 Angioedema

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
Angio Edema
Interventions
DIAGNOSTIC_TEST

Factor XII dosage

Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.

GENETIC

p.Thr328Lys mutation detection

Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.

DIAGNOSTIC_TEST

Videocapillaroscopy

It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.

Trial Locations (1)

1020

CHU Brugmann, Brussels

All Listed Sponsors
lead

Brugmann University Hospital

OTHER

NCT03917680 - Evaluation of New Markers in Type 3 Angioedema | Biotech Hunter | Biotech Hunter